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http:WHAT THIS PAPER ADDS
The technical success rate of ProStar XL for closure of large (20F) femoral vascular access sites in TEVAR was
investigated during a 5-year period. Primary technical failure occurred in 10 of 118 access sites (8%). These cases
were converted to open surgical repair, femoral fascia suturing, or external compression. Primary failure was
associated with hypertension (p ¼ .005), high age (p ¼ .078) and increased groin subcutaneous fat layer
(p ¼ .077). Late access-related complications included pseudo-aneurysms (n ¼ 12), hematomas (n ¼ 7), su-
perﬁcial groin infections (n ¼ 2), and deep venous thrombosis (n ¼ 1). None required surgical treatment.
Tandem ProStar XL closure is safe with few technical failures and few late complications.Objectives: To investigate the technical success rate of Prostar XL for closure of large (20F) femoral vascular
access sites in thoracic endovascular aortic repair (TEVAR) procedures.
Methods: This was a single-center consecutive case series. All TEVAR procedures at Uppsala University Hospital
2006e2010 were registered prospectively. Reoperations and cases with open closure technique were excluded.
Primary (early) technical failure was deﬁned as closure failure requiring immediate (on-table) open surgical
repair; late access-related complication occurred thereafter. The medical records, pre- and postoperative
computed tomography images were reviewed retrospectively.
Results: A total of 164 TEVAR procedures were identiﬁed, of which 118 (71%) had a median 22F (range 20e26F)
access site sealed with tandem Prostar XL. The indications for TEVAR were dissection (47%), aneurysm (42%),
trauma (8%), and miscellaneous (3%). Median follow-up time was 10 months (range 1e62). Primary technical
failure occurred in 10 of 118 (8%). These cases were converted to cut-downs and surgical repair (n ¼ 7), femoral
fascia suturing (n ¼ 2), and external compression with the Femo-Stop device (n ¼ 1). Hypertension was
associated with primary failure (p ¼ .005), and a trend was observed for high age (p ¼ .078) and increased groin
subcutaneous fat layer (p ¼ .077). Late access-related complications included pseudo-aneurysms (n ¼ 12), small
hematomas (n ¼ 7), superﬁcial groin infections (n ¼ 2), and deep venous thrombosis (n ¼ 1). None of the late
complications required surgical treatment.
Conclusions: The access closure technique with tandem Prostar XL for large access sites during TEVAR is safe, in
experienced hands. Few technical failures and few late complications occur, and they are usually benign.
 2013 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
Article history: Received 15 May 2013, Accepted 18 August 2013, Available online 3 September 2013
Keywords: Percutaneous access, Vascular closure device, Thoracic endovascular aortic repair, Pre-close techniqueINTRODUCTION
Thoracic endovascular aortic repair (TEVAR) has become a
feasible option for treatment of several pathologies
affecting the descending thoracic aorta, such as dissec-
tions,1,2 degenerative aneurysms,3,4 and traumatic in-
juries.5e7 The TEVAR procedure requires closure of a large
femoral access site. Several techniques exist: 1) openresponding author. E. Skagius, Department of Surgery, Sundsvall
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//dx.doi.org/10.1016/j.ejvs.2013.08.009technique with cut-down of the femoral artery, 2) modiﬁed
open technique with fascia suture, and 3) totally percuta-
neous technique with suture-mediated vascular closure
devices (SCDs).
Prostar XL (Abbot Vascular, Redwood city, CA, USA) is the
main SCD approved in the European Union for closure of up
to 24F access sites used in a “pre-close technique”.8 A high
rate of procedural success has been reported and it appears
safe and effective in selected patients undergoing percu-
taneous endovascular aortic procedures.9,10 Previous
studies evaluating the effectiveness of Prostar XL in endo-
vascular aortic aneurysm repair have reported on mixed
patient groups, and predominantly on abdominal EVAR
procedures, whereas the number of studied TEVAR vascular
Table 1. Demographics and baseline characteristics. Median
(range) or frequencies (%).
Total number of patients/access sitesa 114/118
Male gender 81 (69%)
Age (yr) 63 (21e85)
Smoking 31 (26%)
BMI (kg/m2) 26 (17e39)
Hypertension 70 (56%)
Diabetes mellitus 10 (8%)
Coronary artery disease 15 (13%)
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pathologies, introducer sheath sizes, and numbers of SCDs
have been included in previous publications.11e22
The primary aim of this study was to investigate the
technical success rate of closure of large (20F) femoral
vascular access sites with the Prostar XL closure device in
TEVAR procedures. A secondary aim was to identify vascular
access-related complications and factors associated with
access closure failure.Cerebrovascular disease 7 (6%)
Chronic obstructive pulmonary disease 21 (18%)
Renal failure 13 (11%)
Connective tissue disease 1 (1%)
Antiplatelet therapy 24 (20%)
Vitamin K antagonist 6 (5%)
Common femoral artery calciﬁcationb 7 (6%)
Subcutaneous fat layer (cm)b 2.6 (0.7e7.1)
a All values are calculated based on access sites, thus four patients
are included twice in the calculations.
b Data available for 81/118 sites.PATIENTS AND METHODS
All TEVAR procedures at the Uppsala University Hospital
between 2006 and 2010 were identiﬁed. All cases of pri-
mary total percutaneous access with a sheath size 20F
were included in the analysis, while sheath size <20F,
reoperations, and non-percutaneous access techniques
were excluded.
All procedures were performed under supervision of
experienced operators familiar with Prostar XL. The com-
mon femoral artery (CFA) was punctured with ultrasound
(US) guidance and two Prostar XL were deployed according
to instruction for use with a 45 rotational angle to each
other. An on-table clinical examination of the patency was
performed at completion. In case of a suspected problem
an US examination was performed to verify/exclude an
access complication. Postoperatively, the patients were kept
in prone position for 6 hours, and vital parameters as well
as the access site were observed.
Primary technical failure was deﬁned as closure failure
requiring immediate (on-table) open surgical repair (i.e.,
cut-down, femoral fascia suturing) or compression therapy
(Femo-Stop, Radi Medical System, Uppsala, Sweden). Late
access-related complication was deﬁned as having occurred
at any time postoperatively (having left the operating
theatre) and was divided into 1) large hematoma requiring
surgical treatment, 2) small hematoma treated conserva-
tively, 3) deep groin infection requiring surgical and anti-
biotic treatment, 4) superﬁcial infection requiring antibiotic
treatment only, 5) occlusion/embolic complication with leg
ischemia, 6) large pseudo-aneurysm requiring surgical
treatment, 7) small pseudo-aneurysm treated conserva-
tively, 8) arteriovenous ﬁstula, and 9) deep venous
thrombosis.
Patients were followed with computed tomography (CT)
angiography and clinical assessment at 1 month, and CT
angiography after 3e6 and 12 months, and thereafter
annually. End of follow-up was deﬁned as the last docu-
mented examination of the groin/access site, either by
physical examination (pulse, no palpable mass) or by CT
scan including the access site.
Data on demographics, comorbidities, medication, pro-
cedural details, and complications were partly entered
prospectively into the Swedvasc registry, and partly
collected retrospectively from the medical records of the
patients. Pre-procedural CT scans were evaluated regarding
CFA calciﬁcation/stenosis and groin subcutaneous fat layer
(SFL). CFA calciﬁcation was deﬁned as more than 50% of thecircumference being calciﬁed, and stenosis as a >50% ste-
nosis at the preoperative axial CT scan. Late local access
complications were recorded from follow-up CT scans and/
or clinical follow-up data.
All patients gave informed consent prior to registration in
the local Swedvasc registry.
The study was approved by the ethics committee of the
Uppsala/Örebro region.
All calculations were analyzed on a per groin basis.
Continuous variables were summarized with medians and
ranges, and categorical variables with frequencies. Contin-
uous data were analyzed using the ManneWhitney U test
and categorical data using the Fisher exact test. Statistical
Package for Social Sciences for Windows (SPSS 19.0, SPSS,
Chicago, IL, USA) was used for data processing and statis-
tical analyses.
RESULTS
A total of 176 TEVAR procedures were identiﬁed. Fifty-eight
procedures were excluded from the analysis: 11 with access
through the aortic arch during open thoracic surgery, one
procedure for treating coarctation (<20F), 25 reoperations
(previous cut-down or Prostar XL closures), 13 with primary
open closure techniques (cut-down or femoral fascia su-
turing), and eight interventions with perioperative events,
such as death or iliac artery injury requiring conversion to
surgical cut-down, preventing the use of the pre-placed
Prostar XL.
The remaining 118 primary TEVAR procedures in 114
patients with total percutaneous femoral access closure
with Prostar XL were included in the analysis. Four of the
procedures were reinterventions, but through an unscarred
groin, that is the contralateral femoral access site was used.
The indications were dissection 47% (acute 57%, chronic
43%), aneurysm 42% (rupture 24%, elective 76%), trauma
(8%), and miscellaneous (3%). Baseline characteristics are
displayed in Table 1.
Table 2. Factors associated with primary failure.
Factors Primary success (n ¼ 108) Primary failure (n ¼ 10) p Value
Age (year) 66 (21e84) 73 (48e85) .078
Male gender 73 (68%) 8 (80%) .50
Smoking 30 (28%) 1 (10%) .45
Hypertension 60 (55%) 10 (100%) .005
Diabetes 8 (7.4%) 2 (20%) .20
Coronary artery disease 14 (13%) 1 (10%) 1.00
Cerebrovascular disease 7 (6.5%) 0 1.00
Chronic obstructive pulmonary disease 18 (17%) 3 (30%) .38
Renal failure 11 (10%) 2 (20%) .30
Connective tissue disease 1 (1%) 0 1.00
Antiplatelet therapy 21 (20%) 3 (30%) .39
Vitamin K antagonist 5 (5%) 1 (10%) .42
Common femoral artery calciﬁcationa 7 (6%) 0 1.00
Subcutaneous fat layer (cm)a 2.7 (2.4e2.9) 3.5 (1.7e5.3) .077
Acute (vs. elective) 47% 20% .18
Aneurysm (vs dissection) 43% 40% .75
a Data available for 81/118 access sites.
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four sutures). Median sheath size was 22F (range 20e26F).
There were eight (7.0%) deaths within the ﬁrst month; none
of them were access related. One had a primary closure
failure treated successfully on-table with fascia suture; the
others were successfully closed with Prostar XL. The median
follow-up time among those surviving 30 days was 10
months (range 1e62). A preoperative CT covering the groin
was available for 81 of 118 access sites and postoperative
CT covering the groin was available for 90 of 118 access
sites, while all surviving patients had postoperative clinical
follow-up data.
Primary technical failure occurred in 10 of 118 (8.5%, 95%
CI 3.0e14%) accessed sites. One was treated non-surgically
with the Femo-Stop device (RADI, Medical System, Uppsala,
Sweden), two with femoral fascia suturing, and seven with
cut-downs and surgical repair. Among the latter, two had
fascia suture attempts and two required a thrombendar-
terectomy. Hypertension was associated with primary fail-
ure (p ¼ .005) and a trend was observed for high age
(p ¼ .078) and increased subcutaneous fat layer (p ¼ .07)
(Table 2).
Late access related complications are displayed in Fig. 1
and Table 3. All bleedings observed postoperatively were
minor hematomas treated conservatively, most were seen
among those with primary failure necessitating open repair.
Two patients were treated with antibiotics for a superﬁcial
groin infection. A total of 12 pseudo-aneurysms were
detected postoperatively. One was of intermediate size
(21 mm). The remaining 11 pseudo-aneurysms were small
(mean/median 8 mm) and were treated conservatively. The
21-mm pseudo-aneurysm was found in a 60-year-old
woman treated for a complex thoracic aneurysm. Post-
operatively, she suffered multiple complications (paraplegia,
intestinal ischemia, and pancreatitis). In that perspective
the pseudo-aneurysm was not considered clinically relevant
and no treatment directed against it was initiated before
she died of septicemia 3 months after the intervention.
According to her medical records the pseudo-aneurysm didnot cause any groin complaints during that time. After a
mean of 20 months of follow-up (median 17 months) none
of the 11 small pseudo-aneurysms had caused any clinical
problem or complaints.DISCUSSION
This single-center study of total percutaneous closure of
large access-sites (20F) is, to our knowledge, the largest
study to date concerning femoral access closure with
Prostar XL in TEVAR patients. The observed high primary
success rate (92%) with few late complications is similar to
previous reports on mixed EVAR and TEVAR patient
groups.9,10
US guidance for precise puncture has been associated
with a lower conversion rate, a higher technical success
rate, and an overall reduction in operative time,18,22 and
may have contributed to the good outcome in the present
report. The use of tandem Prostar XL devices in large access
sites is, however, poorly studied. At our institution these
devices were introduced at the time when Prostar XL was
not approved for closure of access sites larger than 10F. At
that time it was recommended to use two devices for ac-
cess sites larger than 18F. However, according to the most
recent IFU (published in May 2011) access sites larger than
10F may require the use of an additional Prostar XL device.
Although the use of numerous SCDs has the potential to
seal better, it may also complicate closure and cause
vascular damage as well as occlusion and/or stenosis of the
artery.23 Today, we tend to use a single device more often.
All failures in the present report were managed without
any serious complications and no severe late complication
was observed. The most common late access site compli-
cations were minor hematomas and small pseudo-
aneurysms which were treated conservatively. The latter
occurred in 10% of the cases, which is in accordance with
other reports.11e14,16e18,20e22
Patient-related factors such as femoral artery calciﬁca-
tions, obesity, and scarred groins have been reported to
n=7 n=6
n=12
n=2
n=1
TEVAR procedures
n= 164
Prior groin surgery*
n= 25
Primary open closure technique
n= 13
Peri-operative events**: Prostar XL 
closure not completed.
n= 8
TEVAR procedures with Prostar XL
closures
n = 118
Primary success
n= 108
Primary failure
n= 10
Minor haematoma
n=13
Superficial groin 
infection
n=2
Deep venous 
trombosis
n=1
Cut Down n= 7
Fascia suture n= 2
Femo-Stop   n= 1
Pseudoaneurysm#
n=12
Seroma
n=1
n=1
Figure 1. Flowchart depicting the selection of the study population and the occurrence of early and late access-related complications. Late
access-related complications are given in italics. # Eleven pseudo-aneurysms were small (mean 8 mm) and treated conservatively. One
patient had a 21-mm pseudo-aneurysm, but due to multiple complications no treatment directed against it was initiated before she died of
septicemia 3 months after the intervention. *Cut down, previous Prostar XL procedures. **Perioperative death, patient-related factors, for
example iliac artery injuries.
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Table 3. Late access related complications.
Complication Primary
success
(n ¼ 108)
Primary
failure
(n ¼ 10)
Bleeding 7 (6%)a 6 (60%)a
Pseudo-aneurysm 12 (11%)b 0
Groin infection 2 (2%)c 0
Deep venous
thrombosis
1 (1%) 0
Seroma 0 1 (10%)
Stenosis/occlusion 0 0
Arteriovenous ﬁstula 0 0
Nerve entrapment 0 0
a All hematomas were small and treated conservatively.
b Eleven pseudo-aneurysms were small (mean 8 mm) and treated
conservatively. One patient had a 21-mm pseudo-aneurysm, but
due to multiple complications no treatment directed against it was
initiated before she died of septicemia 3 months after the
intervention.
c All infections were superﬁcial and treated with antibiotic alone.
562 E. Skagius et al.contribute to closing failures and in some studies used as
exclusion criteria.10 While no association was seen between
failure and femoral artery calciﬁcation in the present report,
a trend was seen for increasing SFL. SFL exceeding the
length of the Prostar XL hub (5 cm) has been suggested as
an absolute contraindication, while others have found
ProStar XL workable in SFL depth of 10 cm.24 The observed
association between failure and hypertension and a trend
toward higher age among those failed indicate that these
factors may be a proxy for more diseased vessels. In the
present report only primary access was evaluated, while re-
do procedures were excluded. The numbers of included re-
do procedures are small and heterogeneous in most re-
ports,16,19,20,22 which makes them difﬁcult to evaluate.
Even though this is the largest report on TEVAR so far, the
study is limited by the small sample size. With only 10
failures, the study is most likely susceptible to type II sta-
tistical error. In that situation age may be a better proxy for
diseased vessels than calciﬁcation as deﬁned in the present
report. Another important limitation of the present study is
the lack of an evaluation of the importance of the learning
curve of Prostar XL. This was not feasible since all operators
were already experienced with the technique at the time of
evaluation, having acquired experience using the device
during EVAR. In a study on 103 patients (186 femoral ar-
teries), Metcalfe et al.20 found that the operator experience
was a strong predictor of technical success, irrespective of
clinical and morphological characteristics. They used a cut-
off of 20 supervised deployment of the Prostar XL to
deﬁne an experienced operator.20 Our overall experience of
Prostar XL is that the learning curve is long, probably around
20 deployments as suggested by Metcalfe et al., which
constitutes a serious shortcoming of the device.
Perclose ProGlide (Abbot Vascular, Redwood City, CA,
USA) consists of one 3-0, not braided, pre-tied suture for
closure of 6F vascular access sites according to IFU. It may,
however, also be a feasible option for closing large access
sites, and recent studies have reported that “off-label use”of Perclose Proglide is safe and effective for access sites of
18F when using two or more devices,25e28 Since May
2013 ProGlide has been approved for use in 5e21F access
sites in Europe and the United States. According to the IFU,
at least two devices and the pre-close technique are
required for sheath sizes greater than 8F.
Fascia suturing is a minimally invasive surgical alternative
to SCDs, with similar reported technical success rates from
single centers.29e32 It was ﬁrst described by Diethrich in
197733 and consists of suturing the cribriform fascia
covering the CFA. Although more invasive than SCDs, the
lack of pre-closure preparation of the access site may be
beneﬁcial, particularly in emergency situations. Further-
more, in a surgical setting, the fascia suture may be a
cheaper option than the currently available SCDs (T. Larzon,
personal communication, dissertation at Örebro University
2012).
The present study indicates that total percutaneous ac-
cess is feasible and safe for primary TEVAR. This is, however,
only true for experienced operators, since the learning
curve remains an important limitation of the device. No
clear patient factor has been identiﬁed as a contraindication
for Prostar XL, even though severe obesity may hinder the
use of the device. Interestingly we found that emergency
procedures (ruptured thoracic aortic aneurysm and acute
dissection) could also be performed percutaneously. Our
policy is to use Prostar XL on all stable TEVAR patients,
while a post-procedural closure technique, such as cut-
down or fascial suture, is used on unstable patients. With
the next generation of low proﬁle (18F or lower) thoracic
endografts we anticipate an increased success rate of the
Prostar XL approach and that a larger proportion of TEVAR
patients will be suitable for a total percutaneous approach.
CONCLUSION
The access closure technique with tandem Prostar XL for
large access sites during TEVAR is safe in experienced
hands. Few technical failures and late complications occur,
and they are usually benign.
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